MHC class II (HLA-DR) surface expression by latently infected myeloid progenitors. Mock-, AD169-, and RVAdIL10C-infected myeloid progenitors harvested at days 1, 3, 5, 8, 11, and 14 after infection were immunostained for surface MHC class II (HLA-DR). (A) Flow cytometry histogram of cells analyzed at day 8 after infection. (B) The relative fold change in the percentage of MHC class II–positive AD169 or RVAdIL10C-infected myeloid progenitors determined by flow cytometry is shown normalized to the mock-infected value for each individual time point. (C) The relative fold change in the percentage of MHC class II–positive myeloid progenitors on day 8 after infection with either AD169 or RVAdIL10C with or without addition to cultures of 100 ng/mL recombinant viral IL-10 proteins (cmvIL-10 with LAcmvIL-10) on days 6 and 7. The number of independent replicates (n) for each time point is shown. Significant differences between AD169 and RVAdIL10C treatments were determined using 1-tailed, paired Student t test: *P < .05.